Preview

Нефрология

Расширенный поиск

РОЛЬ ВИТАМИНА D В ЗАМЕДЛЕНИИ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК

https://doi.org/10.24884/1561-6274-2008-12-4-20-27

Полный текст:

Аннотация

Дефицит активной формы витамина D - кальцитриола (КТ) определяется на ранних стадиях хронической болезни почек (ХБП) и прогрессирует по мере снижения скорости клубочковой фильтрации вследствие снижения его синтеза в проксимальных канальцах. Снижение уровня КТ является следствием ХБП и в то же время ускоряет ее прогрессирование. В экспериментальных работах и в опытах на животных определены механизмы действия КТ: противовоспалительный, торможение пролиферации мезангиальных клеток и подоцитов клубочков, снижение активности ренин-ангиотензиновой системы, предотвращение гипертрофии клубочков, снижение протеинурии, продукции фиброгенных цитокинов, блокада эпителиально-мезенхимальной трансформации тубулярного эпителия и активации миофибробластов. Благодаря этим эффектам КТ тормозит прогрессирование гломерулярного и тубулоинтерстициального фиброза и тем самым замедляет прогрессирование ХБП. Вместе с тем пока нет проспективных исследований, доказывающих ренопротективный эффект с использования надежных конечных результатов.

Об авторах

А. В. Смирнов
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия

кафедра пропедевтики внутренних болезней

197022 Санкт-Петербург, ул. Л.Толстого 17, СПбГМУ им. акад. И.П. Павлова, тел.:  8-812-234-01-65



М. М. Волков
Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова
Россия

кафедра пропедевтики внутренних болезней

197022 Санкт-Петербург, ул. Л.Толстого 17, СПбГМУ им. акад. И.П. Павлова



Список литературы

1. Tian J, Liu Y, Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007; 22(2): 321-328

2. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-38

3. Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13(3):325-349

4. O’Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D 3 receptor protein in human heart. Cell Biol Int 1996;20(9):621-624

5. Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1,25-dihydroxyvitamin D 3 receptor in the male rat. Biochem Biophys Res Commun 1991 16; 181(2):611-616

6. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73(12):1355-1363

7. Hughson MD, Johnson K, Young RJ et al. Glomerular size and glomerulosclerosis: relationships to disease categories, glomerular solidification, and ischemic obsolescence. Am J Kidney Dis 2002;39(4):679-688.

8. Abdi R, Dong VM, Rubel JR et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003; 170(1): 42-44.

9. Schwarz U, Amann K, Orth SR et al. Effect of 1,25(OH) 2 vitamin D 3 on glomerulosclerosis in subtotally nephrectomized rats. Effect of 1,25(OH) 2vitamin D 3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53(6): 1696-1705

10. Hirata M, Makibayashi K, Katsumata K et al. 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 2002; 17(12): 2132-2137

11. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229–238

12. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88(2):327-331

13. Weinreich T, Merke J, Schonermark M et al. Actions of 1,25-dihydroxyvitamin D 3 on human mesangial cells. Am J Kidney Dis 1991; 18(3): 359-366

14. Panichi V, Migliori M, Taccola D et al. Effects of 1,25(OH)2D 3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001; 60(1):87-95

15. Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158(5):1733-1741

16. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286(3): F526-533

17. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68(6):2823-2828

18. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339(20):1448-1456

19. Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000;11(1):152-176

20. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D 3 receptors in human leukocytes. Science 1983;221(4616):1181-1183

21. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000 15;374(2):334-338

22. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int2001;59(2):415-424

23. Yu XP, Bellido T, Manolagas SC. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D 3. Proc Natl Acad Sci USA1995; 92(24):10990-10994

24. Xing N, L Maldonado ML, Bachman LA et al. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002;297(3): 645-652

25. Panichi V, De Pietro S, Andreini B et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998;54(5):1463-1469

26. Boonstra A, Barrat FJ, Crain C et al. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167(9):4974-4980

27. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8(4):174-179

28. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992;12(2):143-148

29. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R. Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol 1993;94(3):412-417

30. Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylas e. J Clin Endocrinol Metab 2001;86(2):888-894

31. Moe SM, Zekonis M, Harezlak J et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 2001;38(4):792-802

32. Takemoto F, Shinki T, Yokoyama K et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003;64(2): 414-420

33. Healy KD, Frahm MA, DeLuca HF. 1,25-Dihydroxyvitamin D3 up-regulates the renal vitamin D receptor through indirect gene activation and receptor stabilization. Arch Biochem Biophys 2005;433(2):466-473

34. Gekle M. Renal tubule albumin transport. Annu Rev Physiol 2005;67:573-594

35. Weinreich T, Muller A, Wuthrich RP et al. 1,25-dihydroxyvitamin D3 and the synthetic vitamin D analogue, KH 1060, modulate the growth of mouse proximal tubular cells. Kidney Blood Press Res1996;19(6):325-331

36. Li Y, Spataro BC, Yang J et al. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68(4):1500-1510

37. Palmer HG, Gonzalez-Sancho JM, Espada J et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol2001 Jul 23;154(2):369-387

38. Yanagisawa J, Yanagi Y, Masuhiro Y et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283(5406):1317-1321

39. Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA. 1,25-(OH)2D3 alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res2001;100(2):171-175

40. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15(1):1-12

41. Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003;112(4):503-516

42. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17(12):3382-3393

43. Aihara K, Azuma H, Akaike M et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279(34):35798-35802

44. Li X, Zheng W, Li YC. Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem 2003;89(4):709-719

45. Tougaard L, Sorensen E, Brochner-Mortensen J et al. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet 1976;1(7968): 1044-1047

46. Christiansen C, Rodbro P, Christensen MS et al. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978;2(8092 Pt 1):700-703

47. Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310(6976):358-363

48. Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43(5):877-890

49. Ritz E, Kuster S, Schmidt-Gayk H et al. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995;10(12):2228-2234

50. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004;19(4):870-876

51. O’Herrin JK, Hullett DA, Heisey DM et al. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002;22(5-6):515-520

52. de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65(6):2309-2320

53. de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110(8):921-927


Для цитирования:


Смирнов А.В., Волков М.М. РОЛЬ ВИТАМИНА D В ЗАМЕДЛЕНИИ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. Нефрология. 2008;12(4):20-27. https://doi.org/10.24884/1561-6274-2008-12-4-20-27

For citation:


Smirnov A.V., Volkov M.M. THE ROLE OF VITAMIN D IN PROGRESSION OF CHRONIC KIDNEY DISEASE. Nephrology (Saint-Petersburg). 2008;12(4):20-27. (In Russ.) https://doi.org/10.24884/1561-6274-2008-12-4-20-27

Просмотров: 41


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)